Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Drugs In Development, 2022, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 6, 95, 34 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Age Related Macular Degeneration – Overview
Age Related Macular Degeneration – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Age Related Macular Degeneration – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Age Related Macular Degeneration – Companies Involved in Therapeutics Development
3SBio Inc
Abfero Pharmaceuticals Inc
Abzyme Therapeutics LLC
Acahealth Pharma and Biotech Co Ltd
Aerie Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc
Amarna Therapeutics BV
AMD Therapeutics LLC
AmMax Bio Inc
Amyndas Pharmaceuticals LLC
Amytrx Therapeutics Inc
AngioGenex Inc
Anida Pharma Inc
Applied Genetic Technologies Corp
Aptamer Sciences Inc
Ascentage Pharma Group International
Autophagy Science Co Ltd
Avirmax Inc
Baltymas UAB
Beijing StarMab BioMed Technology Ltd
BellBrook Labs LLC
BenoBio Co Ltd
Biokine Therapeutics Ltd
Biomics Biotechnologies Co Ltd
BioXpress Therapeutics SA
Bonac Corp
BrainEver SAS
Breye Therapeutics ApS
Bridge Biotherapeutics Inc
Broadwing Bio
Carmine Therapeutics Inc
CDR-Life Inc
Celon Pharma SA
Celros Biotech Co Ltd
Character Biosciences Co
Charlesson LLC
Chong Kun Dang Pharmaceutical Corporation
Clayton Biotechnologies Inc
Complement Therapeutics Ltd
ConeSight Therapeutics
Curative Biotechnology Inc
CureLab Oncology Inc
Daiichi Sankyo Co Ltd
EirGenix Inc
Epygen Biotech Pvt Ltd
Excitant Therapeutics LLC
Exegenesis Bio Inc
Eye Bio Korea Co Ltd
F. Hoffmann-La Roche Ltd
Feramda Ltd
Galimedix Therapeutics Ltd
Generoath Co Ltd
Glaceum Inc
Great Bay Bio Holdings Ltd
Hanlim Pharm Co Ltd
ICM Co Ltd
Iconic Therapeutics Inc
Immupharma Plc
Inflammasome Therapeutics Inc
Inflammx Therapeutics Inc
Jecho Biopharmaceuticals Co Ltd
Jenivision Inc
JW Pharmaceutical Corp
Kala Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
Lead Discovery Center GmbH
Lineage Cell Therapeutics Inc
Lysoclear Inc
Mabion SA
maintect GmbH
MD Healthcare Inc
MDimune Inc
Mediolanum farmaceutici SpA
MetiMedi Pharmaceuticals Co Ltd
MitoImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Mor Research Applications Ltd
Nextgen Bioscience
NGM Biopharmaceuticals Inc
Novartis AG
Noveome Biotherapeutics Inc
OliPass Corporation
Omeros Corp
Oncosimis Biotech Pvt Ltd
Opsis Therapeutics LLC
Paras Biopharmaceuticals Finland Oy
Perceive Biotherapeutics Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Phio Pharmaceuticals Corp
Phision Therapeutics
PlantForm Corp
Pleryon Therapeutics Ltd
Regeneron Pharmaceuticals Inc
Retrotope Inc
RheinCell Therapeutics GmbH
Rophibio Inc
Rudacure Co Ltd
SeaBeLife Spas
Semathera Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
SIFI SpA
SmartinBio
Splash Pharmaceuticals Inc
Sustained Nano Systems LLC
Suzhou Ribo Life Sciences Co Ltd
Suzhou Stainwei Biotech Inc
Sylentis SAU
TALLC Inc
TechnoPhage SA
Tianchen Biopharmaceutical (Suzhou) Co Ltd
TreeFrog Therapeutics SAS
Trican Biotechnology Co Ltd
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
Valitor Inc
ViGeneron GmbH
Visgenx Inc
Wellstat Ophthalmics Corp
YD Life Science Co
Zhejiang Doer Biologics Corp
Zhuhai Qiwei Biotechnology Co Ltd
Zydus Lifesciences Ltd
Age Related Macular Degeneration – Drug Profiles
601A anti-VEGF Ab – Drug Profile
A-91 – Drug Profile
aflibercept – Drug Profile
aflibercept biosimilar – Drug Profile
Age Related Macular Degeneration – Drug Profile
Age-related Macular Degeneration – Drug Profile
Age-related macular degeneration (AMD) – Drug Profile
AGXA – Drug Profile
AH-601 – Drug Profile
AMA-004 – Drug Profile
AMB-051 – Drug Profile
AMB-057 – Drug Profile
AMD – Drug Profile
AMD-101 – Drug Profile
AMD/DR – Drug Profile
AMTX-100 – Drug Profile
AMY-106 – Drug Profile
Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology – Drug Profile
Antisense RNAi Oligonucleotide for Age Related Macular Degeneration – Drug Profile
Antisense RNAi Oligonucleotide to Inhibit VEGF for Age Related Macular Degeneration – Drug Profile
AS-101 – Drug Profile
AS-301 – Drug Profile
AST-202 – Drug Profile
AVMX-110 – Drug Profile
AVMX-112 – Drug Profile
AVT-101 – Drug Profile
BBRP-11001 – Drug Profile
BBT-401 – Drug Profile
BDR-661 – Drug Profile
bevacizumab – Drug Profile
bevacizumab biosimilar – Drug Profile
Bi-specific Monoclonal Antibodies to Target TfR and VEGF for Age Related Macular Degeneration – Drug Profile
Bi-specific Monoclonal Antibody to Inhibit VEGF and Semaphorin 3A for Age Related Macular Degeneration and Diabetic Macular Edema – Drug Profile
BKT-130 – Drug Profile
BNC-1601 – Drug Profile
BT-2 – Drug Profile
CDR-202 – Drug Profile
Cell Therapy for Age Related Macular Degeneration – Drug Profile
CLT-020 – Drug Profile
ConeProRx – Drug Profile
CPV-103 – Drug Profile
CRB-217 – Drug Profile
CTx-003 – Drug Profile
danicopan – Drug Profile
decitabine – Drug Profile
deulinoleate ethyl – Drug Profile
dexamethasone XR – Drug Profile
DR-30121 – Drug Profile
Drugs to Target GEF-2 for Age Related Macular Degeneration – Drug Profile
EB-203 – Drug Profile
EG-62054 – Drug Profile
ELB-011 – Drug Profile
Elenagen – Drug Profile
Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors – Drug Profile
GAL-201 – Drug Profile
GBB-102 – Drug Profile
Gene Therapy for Age Related Macular Degeneration – Drug Profile
Gene Therapy for Age Related Macular Degeneration and Geographic Atrophy – Drug Profile
Gene Therapy for Age-Related Macular Degeneration – Drug Profile
Gene Therapy to Activate PEDF for Age Related Macular Degeneration – Drug Profile
GFB-204 – Drug Profile
GO-201 – Drug Profile
HL-217 – Drug Profile
hOTX2 for AMD – Drug Profile
HSG-4112 – Drug Profile
HTRA1 – Drug Profile
ICON-4 – Drug Profile
imatinib mesylate – Drug Profile
IPP-204106 – Drug Profile
iptacopan hydrochloride – Drug Profile
JDE-006 – Drug Profile
JP-153 – Drug Profile
JV-MD2 (Omega-3) – Drug Profile
JVMD-1 – Drug Profile
KAL-821 – Drug Profile
KPI-415 – Drug Profile
Lead Compound – Drug Profile
LP-005 – Drug Profile
LQ-015 – Drug Profile
LQ-016 – Drug Profile
LQ-017 – Drug Profile
MDH-001 – Drug Profile
MDH-101 – Drug Profile
metformin – Drug Profile
METI-203 – Drug Profile
MIT-002 – Drug Profile
Monoclonal Antibodies for Age Related Macular Degeneration and Diabetic Retinopathy – Drug Profile
Monoclonal Antibodies to Inhibit VEGF for Age Related Macular Degeneration and Macular Edema – Drug Profile
Monoclonal Antibody for Age Related Macular degeneration – Drug Profile
Monoclonal Antibody for Age-related Macular Degeneration and Glaucoma – Drug Profile
Monoclonal Antibody for Solid Tumors, Metabolic Disorders and Ophthalmology – Drug Profile
Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration – Drug Profile
MT-0814 – Drug Profile
Neuroprotectin D1 – Drug Profile
New Drug Candidate for Age-Related Macular Degeneration – Drug Profile
NX-1901 – Drug Profile
NX-1904 – Drug Profile
NX-1906 – Drug Profile
OPCT-002 – Drug Profile
OPCT-003 – Drug Profile
Oral Therapies for Ophthalmologic Diseases – Drug Profile
PMC-401 – Drug Profile
PMC-403 – Drug Profile
Protein for Metabolic Disorders, Oncology and Ophthalmology – Drug Profile
PSA-20 – Drug Profile
PT-698 – Drug Profile
QA-102 – Drug Profile
quininib – Drug Profile
ranibizumab biosimilar – Drug Profile
RBB-002 – Drug Profile
RBD-5078 – Drug Profile
RCI-005 – Drug Profile
Recombinant Enzyme for Age Related Macular Degeneration and Stargardt Disease – Drug Profile
Recombinant Protein for Age Related Macular Degeneration – Drug Profile
Recombinant Protein to Agonize F2R for Age Related Macular Degeneration – Drug Profile
RS-9 – Drug Profile
RT-002 – Drug Profile
SBL-3 – Drug Profile
SM-2033 – Drug Profile
Small Molecule for Age Related Macular Degeneration – Drug Profile
Small Molecule for Age-Related Macular Degeneration – Drug Profile
Small Molecule for Dry Age Related Macular Degeneration – Drug Profile
Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis – Drug Profile
Small Molecule to Inhibit TRAP1 for Diabetic Retinopathy and Wet Age Related Macular Degeneration – Drug Profile
Small Molecules to Antagonize P2X7 for Age Related Macular Degeneration – Drug Profile
Small Molecules to Inhibit Lanosterol 14-Alpha Demethylase for Age Related Macular Degeneration and Oncology – Drug Profile
Small Molecules to Inhibit MASP2 for Immunology – Drug Profile
SOLOT-Eye – Drug Profile
sorafenib tosylate – Drug Profile
SP-420 – Drug Profile
SPL-108 – Drug Profile
ST-266 – Drug Profile
STC-1 – Drug Profile
Stem Cell Therapy for Age-Related Macular Degeneration – Drug Profile
Stem Cell Therapy for Ophthalmology – Drug Profile
SYL-136001v10 – Drug Profile
TA-111/16 – Drug Profile
TAA-002 – Drug Profile
TRB-002 – Drug Profile
UB-101 – Drug Profile
UB-102 – Drug Profile
UBB-2048 – Drug Profile
UBX-1967 – Drug Profile
UBX-2050 – Drug Profile
VLTR-557 – Drug Profile
XG-19 – Drug Profile
YD-325 – Drug Profile
YDB-201 – Drug Profile
zinpentraxin alfa – Drug Profile
ZRCNB-3224 – Drug Profile
Age Related Macular Degeneration – Dormant Projects
Age Related Macular Degeneration – Discontinued Products
Age Related Macular Degeneration – Product Development Milestones
Featured News & Press Releases
Dec 03, 2022: Valitor announces presentation on novel Anti-VEGF antibody conjugate and Multivalent Polymer technology platform at upcoming Ophthalmology Innovation Source (OIS) Summit
Nov 04, 2022: Aflibercept 8 mg late-breaking data presented at Retina Society in Diabetic Macular Edema and wet age-related macular degeneration
Sep 30, 2022: Aflibercept 8mg positive pivotal results in diabetic macular edema and wet age-related macular degeneration presented at AAO
May 03, 2022: Curative Biotechnology announces toxicology studies under good laboratory practices (GLP) for Metformin eye drop formulations for treatment of macular degeneration
Apr 26, 2022: PharmAbcine announces positive results for its novel TIE2-activating antibody in GLP toxicology study
Mar 21, 2022: Curative Biotechnology announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for clinical evaluation of its proprietary ocular metformin formulation in age-related macular degeneration
Feb 11, 2022: Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at Angiogenesis Meeting
Sep 30, 2021: Inflammasome Therapeutics’ Kamuvudines continue to show promise for future treatment – and potentially a cure – for blindness in seniors
Aug 25, 2021: Regeneron’s aflibercept meets primary goal in Phase II wet AMD trial
Aug 19, 2021: PharmAbcine announces submission of PCT for an Anti-ANG2 antibody for the treatment of ocular diseases
May 10, 2021: PharmAbcine announces encouraging non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 annual meeting
Apr 19, 2021: Inflammasome Therapeutics’ Kamuvudines may be answer to preventing blindness in aging population
Feb 01, 2021: Inflammasome Therapeutics says study published today in proceedings of the National Academy of Sciences provides human data confirming potential of company’s proprietary compounds for prevention of dry AMD
Oct 06, 2020: AbFero announces PK study results For SP-420 In transfusional iron overload -- proceeds with phase 1-2 trial of iron chelator
Jul 31, 2020: Scientists test potential drug developed in Australia to treat common causes of blindness: pre-clinical study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Age Related Macular Degeneration, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
Table 9: Number of Products under Development by Universities/Institutes, 2022
Table 10: Products under Development by Companies, 2022
Table 11: Products under Development by Companies, 2022 (Contd..1)
Table 12: Products under Development by Companies, 2022 (Contd..2)
Table 13: Products under Development by Companies, 2022 (Contd..3)
Table 14: Products under Development by Companies, 2022 (Contd..4)
Table 15: Products under Development by Companies, 2022 (Contd..5)
Table 16: Products under Development by Companies, 2022 (Contd..6)
Table 17: Products under Development by Companies, 2022 (Contd..7)
Table 18: Products under Development by Universities/Institutes, 2022
Table 19: Number of Products by Stage and Target, 2022
Table 20: Number of Products by Stage and Target, 2022 (Contd..1)
Table 21: Number of Products by Stage and Target, 2022 (Contd..2)
Table 22: Number of Products by Stage and Mechanism of Action, 2022
Table 23: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 25: Number of Products by Stage and Route of Administration, 2022
Table 26: Number of Products by Stage and Molecule Type, 2022
Table 27: Age Related Macular Degeneration – Pipeline by 3SBio Inc, 2022
Table 28: Age Related Macular Degeneration – Pipeline by Abfero Pharmaceuticals Inc, 2022
Table 29: Age Related Macular Degeneration – Pipeline by Abzyme Therapeutics LLC, 2022
Table 30: Age Related Macular Degeneration – Pipeline by Acahealth Pharma and Biotech Co Ltd, 2022
Table 31: Age Related Macular Degeneration – Pipeline by Aerie Pharmaceuticals Inc, 2022
Table 32: Age Related Macular Degeneration – Pipeline by Alexion Pharmaceuticals Inc, 2022
Table 33: Age Related Macular Degeneration – Pipeline by Alkeus Pharmaceuticals Inc, 2022
Table 34: Age Related Macular Degeneration – Pipeline by Amarna Therapeutics BV, 2022
Table 35: Age Related Macular Degeneration – Pipeline by AMD Therapeutics LLC, 2022
Table 36: Age Related Macular Degeneration – Pipeline by AmMax Bio Inc, 2022
Table 37: Age Related Macular Degeneration – Pipeline by Amyndas Pharmaceuticals LLC, 2022
Table 38: Age Related Macular Degeneration – Pipeline by Amytrx Therapeutics Inc, 2022
Table 39: Age Related Macular Degeneration – Pipeline by AngioGenex Inc, 2022
Table 40: Age Related Macular Degeneration – Pipeline by Anida Pharma Inc, 2022
Table 41: Age Related Macular Degeneration – Pipeline by Applied Genetic Technologies Corp, 2022
Table 42: Age Related Macular Degeneration – Pipeline by Aptamer Sciences Inc, 2022
Table 43: Age Related Macular Degeneration – Pipeline by Ascentage Pharma Group International, 2022
Table 44: Age Related Macular Degeneration – Pipeline by Autophagy Science Co Ltd, 2022
Table 45: Age Related Macular Degeneration – Pipeline by Avirmax Inc, 2022
Table 46: Age Related Macular Degeneration – Pipeline by Baltymas UAB, 2022
Table 47: Age Related Macular Degeneration – Pipeline by Beijing StarMab BioMed Technology Ltd, 2022
Table 48: Age Related Macular Degeneration – Pipeline by BellBrook Labs LLC, 2022
Table 49: Age Related Macular Degeneration – Pipeline by BenoBio Co Ltd, 2022
Table 50: Age Related Macular Degeneration – Pipeline by Biokine Therapeutics Ltd, 2022
Table 51: Age Related Macular Degeneration – Pipeline by Biomics Biotechnologies Co Ltd, 2022
Table 52: Age Related Macular Degeneration – Pipeline by BioXpress Therapeutics SA, 2022
Table 53: Age Related Macular Degeneration – Pipeline by Bonac Corp, 2022
Table 54: Age Related Macular Degeneration – Pipeline by BrainEver SAS, 2022
Table 55: Age Related Macular Degeneration – Pipeline by Breye Therapeutics ApS, 2022
Table 56: Age Related Macular Degeneration – Pipeline by Bridge Biotherapeutics Inc, 2022
Table 57: Age Related Macular Degeneration – Pipeline by Broadwing Bio, 2022
Table 58: Age Related Macular Degeneration – Pipeline by Carmine Therapeutics Inc, 2022
Table 59: Age Related Macular Degeneration – Pipeline by CDR-Life Inc, 2022
Table 60: Age Related Macular Degeneration – Pipeline by Celon Pharma SA, 2022
Table 61: Age Related Macular Degeneration – Pipeline by Celros Biotech Co Ltd, 2022
Table 62: Age Related Macular Degeneration – Pipeline by Character Biosciences Co, 2022
Table 63: Age Related Macular Degeneration – Pipeline by Charlesson LLC, 2022
Table 64: Age Related Macular Degeneration – Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022
Table 65: Age Related Macular Degeneration – Pipeline by Clayton Biotechnologies Inc, 2022
Table 66: Age Related Macular Degeneration – Pipeline by Complement Therapeutics Ltd, 2022
Table 67: Age Related Macular Degeneration – Pipeline by ConeSight Therapeutics, 2022
Table 68: Age Related Macular Degeneration – Pipeline by Curative Biotechnology Inc, 2022
Table 69: Age Related Macular Degeneration – Pipeline by CureLab Oncology Inc, 2022
Table 70: Age Related Macular Degeneration – Pipeline by Daiichi Sankyo Co Ltd, 2022
Table 71: Age Related Macular Degeneration – Pipeline by EirGenix Inc, 2022
Table 72: Age Related Macular Degeneration – Pipeline by Epygen Biotech Pvt Ltd, 2022
Table 73: Age Related Macular Degeneration – Pipeline by Excitant Therapeutics LLC, 2022
Table 74: Age Related Macular Degeneration – Pipeline by Exegenesis Bio Inc, 2022
Table 75: Age Related Macular Degeneration – Pipeline by Eye Bio Korea Co Ltd, 2022
Table 76: Age Related Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 77: Age Related Macular Degeneration – Pipeline by Feramda Ltd, 2022
Table 78: Age Related Macular Degeneration – Pipeline by Galimedix Therapeutics Ltd, 2022
Table 79: Age Related Macular Degeneration – Pipeline by Generoath Co Ltd, 2022
Table 80: Age Related Macular Degeneration – Pipeline by Glaceum Inc, 2022
Table 81: Age Related Macular Degeneration – Pipeline by Great Bay Bio Holdings Ltd, 2022
Table 82: Age Related Macular Degeneration – Pipeline by Hanlim Pharm Co Ltd, 2022
Table 83: Age Related Macular Degeneration – Pipeline by ICM Co Ltd, 2022
Table 84: Age Related Macular Degeneration – Pipeline by Iconic Therapeutics Inc, 2022
Table 85: Age Related Macular Degeneration – Pipeline by Immupharma Plc, 2022
Table 86: Age Related Macular Degeneration – Pipeline by Inflammasome Therapeutics Inc, 2022
Table 87: Age Related Macular Degeneration – Pipeline by Inflammx Therapeutics Inc, 2022
Table 88: Age Related Macular Degeneration – Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Table 89: Age Related Macular Degeneration – Pipeline by Jenivision Inc, 2022
Table 90: Age Related Macular Degeneration – Pipeline by JW Pharmaceutical Corp, 2022
Table 91: Age Related Macular Degeneration – Pipeline by Kala Pharmaceuticals Inc, 2022
Table 92: Age Related Macular Degeneration – Pipeline by Kiora Pharmaceuticals Inc, 2022
Table 93: Age Related Macular Degeneration – Pipeline by Lead Discovery Center GmbH, 2022
Table 94: Age Related Macular Degeneration – Pipeline by Lineage Cell Therapeutics Inc, 2022
Table 95: Age Related Macular Degeneration – Pipeline by Lysoclear Inc, 2022
Table 96: Age Related Macular Degeneration – Pipeline by Mabion SA, 2022
Table 97: Age Related Macular Degeneration – Pipeline by maintect GmbH, 2022
Table 98: Age Related Macular Degeneration – Pipeline by MD Healthcare Inc, 2022
Table 99: Age Related Macular Degeneration – Pipeline by MDimune Inc, 2022
Table 100: Age Related Macular Degeneration – Pipeline by Mediolanum farmaceutici SpA, 2022
Table 101: Age Related Macular Degeneration – Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2022
Table 102: Age Related Macular Degeneration – Pipeline by MitoImmune Therapeutics Inc, 2022
Table 103: Age Related Macular Degeneration – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Table 104: Age Related Macular Degeneration – Pipeline by Mor Research Applications Ltd, 2022
Table 105: Age Related Macular Degeneration – Pipeline by Nextgen Bioscience, 2022
Table 106: Age Related Macular Degeneration – Pipeline by NGM Biopharmaceuticals Inc, 2022
Table 107: Age Related Macular Degeneration – Pipeline by Novartis AG, 2022
Table 108: Age Related Macular Degeneration – Pipeline by Noveome Biotherapeutics Inc, 2022
Table 109: Age Related Macular Degeneration – Pipeline by OliPass Corporation, 2022
Table 110: Age Related Macular Degeneration – Pipeline by Omeros Corp, 2022
Table 111: Age Related Macular Degeneration – Pipeline by Oncosimis Biotech Pvt Ltd, 2022
Table 112: Age Related Macular Degeneration – Pipeline by Opsis Therapeutics LLC, 2022
Table 113: Age Related Macular Degeneration – Pipeline by Paras Biopharmaceuticals Finland Oy, 2022
Table 114: Age Related Macular Degeneration – Pipeline by Perceive Biotherapeutics Inc, 2022
Table 115: Age Related Macular Degeneration – Pipeline by Phanes Therapeutics Inc, 2022
Table 116: Age Related Macular Degeneration – Pipeline by PharmAbcine Inc, 2022
Table 117: Age Related Macular Degeneration – Pipeline by Phio Pharmaceuticals Corp, 2022
Table 118: Age Related Macular Degeneration – Pipeline by Phision Therapeutics, 2022
Table 119: Age Related Macular Degeneration – Pipeline by PlantForm Corp, 2022
Table 120: Age Related Macular Degeneration – Pipeline by Pleryon Therapeutics Ltd, 2022
Table 121: Age Related Macular Degeneration – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 122: Age Related Macular Degeneration – Pipeline by Retrotope Inc, 2022
Table 123: Age Related Macular Degeneration – Pipeline by RheinCell Therapeutics GmbH, 2022
Table 124: Age Related Macular Degeneration – Pipeline by Rophibio Inc, 2022
Table 125: Age Related Macular Degeneration – Pipeline by Rudacure Co Ltd, 2022
Table 126: Age Related Macular Degeneration – Pipeline by SeaBeLife Spas, 2022
Table 127: Age Related Macular Degeneration – Pipeline by Semathera Inc, 2022
Table 128: Age Related Macular Degeneration – Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022
Table 129: Age Related Macular Degeneration – Pipeline by SIFI SpA, 2022
Table 130: Age Related Macular Degeneration – Pipeline by SmartinBio, 2022
Table 131: Age Related Macular Degeneration – Pipeline by Splash Pharmaceuticals Inc, 2022
Table 132: Age Related Macular Degeneration – Pipeline by Sustained Nano Systems LLC, 2022
Table 133: Age Related Macular Degeneration – Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Table 134: Age Related Macular Degeneration – Pipeline by Suzhou Stainwei Biotech Inc, 2022
Table 135: Age Related Macular Degeneration – Pipeline by Sylentis SAU, 2022
Table 136: Age Related Macular Degeneration – Pipeline by TALLC Inc, 2022
Table 137: Age Related Macular Degeneration – Pipeline by TechnoPhage SA, 2022
Table 138: Age Related Macular Degeneration – Pipeline by Tianchen Biopharmaceutical (Suzhou) Co Ltd, 2022
Table 139: Age Related Macular Degeneration – Pipeline by TreeFrog Therapeutics SAS, 2022
Table 140: Age Related Macular Degeneration – Pipeline by Trican Biotechnology Co Ltd, 2022
Table 141: Age Related Macular Degeneration – Pipeline by Uni-Bio Science Group Ltd, 2022
Table 142: Age Related Macular Degeneration – Pipeline by Unity Biotechnology Inc, 2022
Table 143: Age Related Macular Degeneration – Pipeline by Valitor Inc, 2022
Table 144: Age Related Macular Degeneration – Pipeline by ViGeneron GmbH, 2022
Table 145: Age Related Macular Degeneration – Pipeline by Visgenx Inc, 2022
Table 146: Age Related Macular Degeneration – Pipeline by Wellstat Ophthalmics Corp, 2022
Table 147: Age Related Macular Degeneration – Pipeline by YD Life Science Co, 2022
Table 148: Age Related Macular Degeneration – Pipeline by Zhejiang Doer Biologics Corp, 2022
Table 149: Age Related Macular Degeneration – Pipeline by Zhuhai Qiwei Biotechnology Co Ltd, 2022
Table 150: Age Related Macular Degeneration – Pipeline by Zydus Lifesciences Ltd, 2022
Table 151: Age Related Macular Degeneration – Dormant Projects, 2022
Table 152: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..1)
Table 153: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..2)
Table 154: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..3)
Table 155: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..4)
Table 156: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..5)
Table 157: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..6)
Table 158: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..7)
Table 159: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..8)
Table 160: Age Related Macular Degeneration – Dormant Projects, 2022 (Contd..9)
Table 161: Age Related Macular Degeneration – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Age Related Macular Degeneration, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings